{"ALECR.PA": {"short_name": "EUROFINS CEREP", "long_name": "Eurofins-Cerep SA", "summary": "Eurofins Cerep SA provides various drug discovery services to pharmaceutical and biotechnology companies worldwide. The company's research services include compound management, high-throughput screening, in vitro safety profiling, lead optimization (or SAR) profiling, in vitro ADME profiling, and in vivo PK. It also offers assay design and development services. The company was formerly known as Cerep SA and changed its name to Eurofins Cerep SA in June 2014. Eurofins Cerep SA was founded in 1989 and is based in Vienne, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Vienne"}, "SAN.PA": {"short_name": "SANOFI", "long_name": "Sanofi", "summary": "Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; Kymera Therapeutics; Parkinson's Foundation, Inc.; and Nurix Therapeutics, Inc. The company was formerly known as Sanofi-Aventis. Sanofi was incorporated in 1994 and is headquartered in Paris, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Paris"}, "SANF.MI": {"short_name": "SANOFI", "long_name": "Sanofi", "summary": "Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; Kymera Therapeutics; Parkinson's Foundation, Inc.; and Nurix Therapeutics, Inc. The company was formerly known as Sanofi-Aventis. Sanofi was incorporated in 1994 and is headquartered in Paris, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "MIL", "market": "it_market", "country": "France", "city": "Paris"}, "SANO.VI": {"short_name": "SANOFI SA", "long_name": "Sanofi", "summary": "Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; Kymera Therapeutics; Parkinson's Foundation, Inc.; and Nurix Therapeutics, Inc. The company was formerly known as Sanofi-Aventis. Sanofi was incorporated in 1994 and is headquartered in Paris, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "VIE", "market": "at_market", "country": "France", "city": "Paris"}, "SNW.DE": {"short_name": "SANOFI SA INHABER  EO 2", "long_name": "Sanofi", "summary": "Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; Kymera Therapeutics; Parkinson's Foundation, Inc.; and Nurix Therapeutics, Inc. The company was formerly known as Sanofi-Aventis. Sanofi was incorporated in 1994 and is headquartered in Paris, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "GER", "market": "de_market", "country": "France", "city": "Paris"}, "SNW.F": {"short_name": "SANOFI SA INHABER  EO 2", "long_name": "Sanofi", "summary": "Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; Kymera Therapeutics; Parkinson's Foundation, Inc.; and Nurix Therapeutics, Inc. The company was formerly known as Sanofi-Aventis. Sanofi was incorporated in 1994 and is headquartered in Paris, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "FRA", "market": "dr_market", "country": "France", "city": "Paris"}, "SNY": {"short_name": "Sanofi", "long_name": "Sanofi", "summary": "Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; Kymera Therapeutics; Parkinson's Foundation, Inc.; and Nurix Therapeutics, Inc. The company was formerly known as Sanofi-Aventis. Sanofi was incorporated in 1994 and is headquartered in Paris, France.", "currency": "USD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "NMS", "market": "us_market", "country": "France", "city": "Paris"}, "SNYNF": {"short_name": "SANOFI", "long_name": "Sanofi", "summary": "Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; Kymera Therapeutics; Parkinson's Foundation, Inc.; and Nurix Therapeutics, Inc. The company was formerly known as Sanofi-Aventis. Sanofi was incorporated in 1994 and is headquartered in Paris, France.", "currency": "USD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "PNK", "market": "us_market", "country": "France", "city": "Paris"}, "V16.F": {"short_name": "VIRBAC SA  EO 1,25", "long_name": "Virbac SA", "summary": "Virbac SA produces and sells medicines and vaccines for companion and food-producing animals in France and internationally. The company offers Anibidiol, a food supplement in powder/granulate form; Alizine, a contraceptive for dogs; Boviseal, a suspension to prevent intramammary infections; Bovigen Scour, a vaccine used to protect calves against viral and bacterial infections; Browse Plus, a food supplement for food producing animals; and C.E.T. Veggiedent Flex, C.E.T. Veggiedent Fr3sh, and C.E.T. Veggiedent Zen to treat bad breath in dogs. It also provides Clostrisan, a vaccine for the prevention of clostridiosis and botulism; Easotic, an auricular treatment for otitis; Effipro bovis to treat tick, flea, and louse infestations; Epiotic, an ear cleanser; Eradia to treat clostridium infections and giardiasis; Evicto, a selamectin-based endectocide treatment; Fosfosal, a trace mineral injectable supplementation; and Grofactor, a growth promoter. In addition, the company offers Hyaloral, a food supplement in tablet or gel form; Kriptazen, a halofuginone-based antiprotozoal solution; Luminal, phenobarbital-based tablet; Milpro, an internal parasiticide tablets; Moxiheart, an internal parasiticide; and Multimin, a trace element injectable supplement; Nutri-plus gel, a food supplement in oral gel form; Prevendog, deltamethrin-based parasiticides collar; Pronefra, a food supplement in case of chronic kidney disease; and Sentinel Flavor Tabs et Sentinel Spectrum, a polyvalent parasiticide tablet. Further, it provides Shotapen to treat bacterial infections; Suigen PCV2, a vaccine against porcine circovirus; Suramox, a coated amoxicillin-based antibiotic; Suprelorin, a deslorelin-based implant; Syvazul, a bluetongue vaccine; Vetemex, an antiemetic solution; Virbagest, an altrenogest-based progestin; Virbamec Platinum, an injectable solution; and Zoletil, a multi-species general anesthetic. Virbac SA was founded in 1968 and is headquartered in Carros, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "FRA", "market": "dr_market", "country": "France", "city": "Carros"}, "VIRP.PA": {"short_name": "VIRBAC", "long_name": "Virbac SA", "summary": "Virbac SA produces and sells medicines and vaccines for companion and food-producing animals in France and internationally. The company offers Anibidiol, a food supplement in powder/granulate form; Alizine, a contraceptive for dogs; Boviseal, a suspension to prevent intramammary infections; Bovigen Scour, a vaccine used to protect calves against viral and bacterial infections; Browse Plus, a food supplement for food producing animals; and C.E.T. Veggiedent Flex, C.E.T. Veggiedent Fr3sh, and C.E.T. Veggiedent Zen to treat bad breath in dogs. It also provides Clostrisan, a vaccine for the prevention of clostridiosis and botulism; Easotic, an auricular treatment for otitis; Effipro bovis to treat tick, flea, and louse infestations; Epiotic, an ear cleanser; Eradia to treat clostridium infections and giardiasis; Evicto, a selamectin-based endectocide treatment; Fosfosal, a trace mineral injectable supplementation; and Grofactor, a growth promoter. In addition, the company offers Hyaloral, a food supplement in tablet or gel form; Kriptazen, a halofuginone-based antiprotozoal solution; Luminal, phenobarbital-based tablet; Milpro, an internal parasiticide tablets; Moxiheart, an internal parasiticide; and Multimin, a trace element injectable supplement; Nutri-plus gel, a food supplement in oral gel form; Prevendog, deltamethrin-based parasiticides collar; Pronefra, a food supplement in case of chronic kidney disease; and Sentinel Flavor Tabs et Sentinel Spectrum, a polyvalent parasiticide tablet. Further, it provides Shotapen to treat bacterial infections; Suigen PCV2, a vaccine against porcine circovirus; Suramox, a coated amoxicillin-based antibiotic; Suprelorin, a deslorelin-based implant; Syvazul, a bluetongue vaccine; Vetemex, an antiemetic solution; Virbagest, an altrenogest-based progestin; Virbamec Platinum, an injectable solution; and Zoletil, a multi-species general anesthetic. Virbac SA was founded in 1968 and is headquartered in Carros, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Carros"}}